Genmab reported DKK2.58B in Net Income for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Agios Pharmaceuticals AGIO:US USD -81747000 10.06M
Amarin AMRN:US USD -5140000 64.82M
Amgen AMGN:US USD 2.14B 826M
Artemis Alpha ATS:LN GBP -26769000 16.52M
AstraZeneca AZN:LN USD 1.64B 1.28B
Bayer BAYN:GR EUR 546M 844M
Biomarin Pharmaceutical BMRN:US USD -6652000 34.32M
Bluebird Bio BLUE:US USD -76520000 23.62M
Exelixis EXEL:US USD 73.21M 2.54M
Fresenius Medical Care FME:GR EUR 230M 83M
Galapagos GLPG:NA EUR 21.55M 40.58M
Genmab GEN:DC DKK 2.58B 691M
GlaxoSmithKline GSK:LN GBP 10.32B 9.48B
GN Store Nord GN:DC DKK 197M 45M
Hikma Pharmaceutical HIK:LN USD 173M 0
Immunogen IMGN:US USD -77755000 15.73M
Insmed INSM:US USD -131145000 35.5M
Lonza Group LONN:SW CHF 492M 2.13B
Merck MRK:GR EUR 923M 56M
Novartis NOVN:VX USD 1.57B 121M
Regeneron Pharmaceuticals REGN:US USD 1.32B 463.6M
Roche Holding ROG:VX 8.53B 2.4B
Seattle Genetics SGEN:US USD -190816000 55.99M
William Demant Holding WDH:DC DKK 1.05B 290M